Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H28N2O8S2 |
| Molecular Weight | 500.586 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1OC)S(=O)(=O)N2CCCN(CC2)S(=O)(=O)C3=CC=C(OC)C(OC)=C3
InChI
InChIKey=GJUFPAZNBPFNRI-UHFFFAOYSA-N
InChI=1S/C21H28N2O8S2/c1-28-18-8-6-16(14-20(18)30-3)32(24,25)22-10-5-11-23(13-12-22)33(26,27)17-7-9-19(29-2)21(15-17)31-4/h6-9,14-15H,5,10-13H2,1-4H3
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q8TDU6 Gene ID: 151306.0 Gene Symbol: GPBAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27121782 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
F3EST236LD
Created by
admin on Tue Apr 01 16:39:39 GMT 2025 , Edited by admin on Tue Apr 01 16:39:39 GMT 2025
|
PRIMARY | |||
|
DTXSID201025986
Created by
admin on Tue Apr 01 16:39:39 GMT 2025 , Edited by admin on Tue Apr 01 16:39:39 GMT 2025
|
PRIMARY | |||
|
1520267
Created by
admin on Tue Apr 01 16:39:39 GMT 2025 , Edited by admin on Tue Apr 01 16:39:39 GMT 2025
|
PRIMARY | |||
|
447410-57-3
Created by
admin on Tue Apr 01 16:39:39 GMT 2025 , Edited by admin on Tue Apr 01 16:39:39 GMT 2025
|
PRIMARY | |||
|
SB-756050
Created by
admin on Tue Apr 01 16:39:39 GMT 2025 , Edited by admin on Tue Apr 01 16:39:39 GMT 2025
|
PRIMARY | A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral SB756050 Administered for 6 Days to Subjects With Type 2 Diabetes Mellitus Purpose: This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics. |
ACTIVE MOIETY